191 related articles for article (PubMed ID: 25209580)
21. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
22. BRAF
Vaughn JL; Freitag CE; Hemminger JA; Jones JA
J Med Case Rep; 2017 Apr; 11(1):92. PubMed ID: 28376906
[TBL] [Abstract][Full Text] [Related]
23. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
[No Abstract] [Full Text] [Related]
24. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
Young K; Minchom A; Larkin J
Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
[TBL] [Abstract][Full Text] [Related]
25. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
26. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Peters S; Michielin O; Zimmermann S
J Clin Oncol; 2013 Jul; 31(20):e341-4. PubMed ID: 23733758
[No Abstract] [Full Text] [Related]
27. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
28. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
[No Abstract] [Full Text] [Related]
29. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
[TBL] [Abstract][Full Text] [Related]
30. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor.
Aylwin SJ; Bodi I; Beaney R
Pituitary; 2016 Oct; 19(5):544-6. PubMed ID: 26115708
[No Abstract] [Full Text] [Related]
31. Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.
Ji G; Qian Y
Clin Genitourin Cancer; 2017 Aug; 15(4):e719-e721. PubMed ID: 28024948
[No Abstract] [Full Text] [Related]
32. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.
Raab MS; Lehners N; Xu J; Ho AD; Schirmacher P; Goldschmidt H; Andrulis M
Blood; 2016 Apr; 127(17):2155-7. PubMed ID: 26884375
[No Abstract] [Full Text] [Related]
33. A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::BRAF fusion: a case report and literature review.
Zhang L; Zhang G; Zheng H; Jiang B; Ju Y; Duan Q; An L; Shi H
Brain Tumor Pathol; 2024 Jan; 41(1):18-29. PubMed ID: 38100030
[TBL] [Abstract][Full Text] [Related]
34. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
35. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
36. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
[TBL] [Abstract][Full Text] [Related]
37. Secondary histiocytic sarcoma with BRAF
Venkataraman V; Massoth LR; Sullivan RJ; Friedmann AM
Pediatr Blood Cancer; 2021 Oct; 68(10):e29166. PubMed ID: 34061432
[No Abstract] [Full Text] [Related]
38. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
39. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Kordes M; Röring M; Heining C; Braun S; Hutter B; Richter D; Geörg C; Scholl C; Gröschel S; Roth W; Rosenwald A; Geissinger E; von Kalle C; Jäger D; Brors B; Weichert W; Grüllich C; Glimm H; Brummer T; Fröhling S
Leukemia; 2016 Apr; 30(4):937-46. PubMed ID: 26582644
[TBL] [Abstract][Full Text] [Related]
40. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
